Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 1
2006 1
2007 2
2008 2
2009 6
2010 6
2011 2
2012 1
2020 4
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. Ho AL, et al. Among authors: gualberto a. J Clin Oncol. 2021 Jun 10;39(17):1856-1864. doi: 10.1200/JCO.20.02903. Epub 2021 Mar 22. J Clin Oncol. 2021. PMID: 33750196 Free PMC article. Clinical Trial.
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.
Rodríguez M, Alonso-Alonso R, Tomás-Roca L, Rodríguez-Pinilla SM, Manso-Alonso R, Cereceda L, Borregón J, Villaescusa T, Córdoba R, Sánchez-Beato M, Fernández-Miranda I, Betancor I, Bárcena C, García JF, Mollejo M, García-Cosio M, Martin-Acosta P, Climent F, Caballero D, de la Fuente L, Mínguez P, Kessler L, Scholz C, Gualberto A, Mondéjar R, Piris MA. Rodríguez M, et al. Among authors: gualberto a. Blood Adv. 2021 Dec 28;5(24):5588-5598. doi: 10.1182/bloodadvances.2021005171. Blood Adv. 2021. PMID: 34592752 Free PMC article.
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Steensma DP, et al. Among authors: gualberto a. Leukemia. 2021 Dec;35(12):3542-3550. doi: 10.1038/s41375-021-01328-9. Epub 2021 Jun 25. Leukemia. 2021. PMID: 34172893 Free PMC article. Clinical Trial.
Figitumumab (CP-751,871) for cancer therapy.
Gualberto A. Gualberto A. Expert Opin Biol Ther. 2010 Apr;10(4):575-85. doi: 10.1517/14712591003689980. Expert Opin Biol Ther. 2010. PMID: 20175655 Review.
Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway.
Hixon ML, Paccagnella L, Millham R, Perez-Olle R, Gualberto A. Hixon ML, et al. Among authors: gualberto a. Rev Recent Clin Trials. 2010 Sep;5(3):189-208. doi: 10.2174/157488710792007329. Rev Recent Clin Trials. 2010. PMID: 20533896 Review.
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL. Hanna GJ, et al. Among authors: gualberto a. Cancer. 2020 Sep 1;126(17):3972-3981. doi: 10.1002/cncr.33036. Epub 2020 Jun 18. Cancer. 2020. PMID: 32557577 Free PMC article. Clinical Trial.
28 results